医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma

2016年03月28日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that an Asian Multinational Phase II study of SP-02 (darinaparsin) for injection (SP-02L) for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) has commenced. This single-arm, open-label, non-randomized study is being conducted in Japan, South Korea, Taiwan and Hong Kong; to evaluate the efficacy and safety of SP-02L monotherapy.

SP-02 is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, SP-02 demonstrated clinical activity in lymphoma, in particular PTCL. In Phase I studies, in Japan and South Korea, safety and potential efficacy against PTCL have also been demonstrated. Based on the Phase II result, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong.

Solasia obtained an exclusive worldwide license to develop and commercialize SP-02 from ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), and the company is currently conducting clinical trials in Japan and other parts of Asia. Solasia granted development and commercialization rights of SP-02 in Japan to Meiji Seika Pharma Co. Ltd.

About Solasia:

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia recently completed Series D financing of JPY2.08 billion in August 2015. The funds will be used to prepare for launch of Sancuso® and further advance clinical development of its existing pipeline. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20160327005013/en/

CONTACT

Solasia Pharma K.K.
Koji Shinozaki, +81-3-6721-8330
Vice
President, Business Development
kshinozaki@solasia.co.jp
or
Annes
Associates
Shari Annes, +1-650-888-0902
sannes@annesassociates.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定